Niagen Bioscience (NASDAQ:NAGE) Reaches New 12-Month High - What's Next?

Niagen Bioscience Inc (NASDAQ:NAGE - Get Free Report)'s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $11.84 and last traded at $11.78, with a volume of 1011127 shares changing hands. The stock had previously closed at $11.73.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Roth Capital boosted their price target on Niagen Bioscience from $10.00 to $23.00 and gave the company a "buy" rating in a report on Friday. Canaccord Genuity Group assumed coverage on Niagen Bioscience in a report on Tuesday, May 27th. They issued a "buy" rating and a $13.00 price target on the stock. Finally, Wall Street Zen lowered Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a report on Friday.

Niagen Bioscience Trading Up 12.5%

The company has a market cap of $1.02 billion, a price-to-earnings ratio of 76.18 and a beta of 2.08. The stock has a fifty day moving average price of $8.56.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.